Silo Pharma has entered into an agreement with WuXi AppTec for a preclinical small animal study of SPU-16, a central nervous system homing peptide targeting multiple sclerosis. Silo Pharma is advancing the development of the SPU-16 liposomal homing peptide through a commercial evaluation license and option agreement with the University of Maryland, Baltimore. The study will examine the organ/tissue specificity of the SPU-16 peptide in an experimental autoimmune encephalomyelitis protocol, is the most commonly used experimental model for MS. The peptide’s proven ability to target inflamed epithelium suggests that it can be used as a targeted drug delivery tool to address inflammation in the spinal cord.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SILO:
- Silo Pharma Announces Partnership with Global CRO for Central Nervous System Homing Peptide
- Silo Pharma to Present at H.C. Wainwright Annual Global Investment Conference
- Silo Pharma to present on SPC-15 at H.C. Wainwright conference
- Silo Pharma Announces Closing of $2.1 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
- Silo Pharma to sell 763,638 shares at $2.75 in registered direct offering